MedChunk
Medically reviewed

Biologic Side Effects in Ankylosing Spondylitis

Learn about common and serious biologic side effects in ankylosing spondylitis, including infection risks, injection reactions, safety checks, and warning signs.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateNov 19, 2026 16 min read

Biologic medicines used for ankylosing spondylitis can cause side effects such as redness at the injection site, headaches, stomach problems, and an increased risk of infections. More serious problems, including severe infections or allergic reactions, are less common but need medical attention. Many people take biologics successfully, and regular health checks help doctors identify possible problems during treatment.

Why Do Biologic Medicines Cause Side Effects?

Biologic medicines reduce inflammation by targeting specific parts of the immune system. In ankylosing spondylitis (AS), the immune system contributes to ongoing inflammation, particularly around the spine and the joints connecting the spine to the pelvis.

Reducing this inflammation can ease back pain, morning stiffness, and other symptoms. However, the immune system also protects the body against infections. Changing how certain immune responses work may make it harder to fight some germs.

Biologic medicines are generally considered when symptoms remain active despite other treatments, including anti-inflammatory medicines and exercise. According to the NHS guidance on ankylosing spondylitis treatment, biologic treatments can help control inflammation, but patients receiving anti-TNF medicines need monitoring because of the possibility of serious infections.

The side effects depend partly on which biologic medicine is prescribed. A reaction associated with one drug is not necessarily expected with every biologic.

Which Biologics Are Used for Ankylosing Spondylitis?

Two important groups of biologic medicines used for ankylosing spondylitis are tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) inhibitors. Both reduce inflammation, but they target different parts of the immune system.

TNF inhibitors

TNF inhibitors block tumor necrosis factor, a protein involved in inflammation. Examples include adalimumab, etanercept, infliximab, golimumab, and certolizumab pegol.

These medicines may be given as injections under the skin or, for certain products, through an intravenous infusion. Their important safety concerns include infections, injection or infusion reactions, and several less common immune-related complications.

IL-17 inhibitors

IL-17 inhibitors block inflammatory signaling involving interleukin-17. Examples used in ankylosing spondylitis include secukinumab and ixekizumab.

These medicines can also increase the risk of infections. Some IL-17 inhibitors are associated with fungal infections and new or worsening inflammatory bowel disease, making digestive health an important consideration when choosing treatment.

The Merck Manual's clinical review of ankylosing spondylitis describes upper respiratory infections, Candida fungal infections, diarrhea, and worsening inflammatory bowel disease among potential adverse effects of IL-17 inhibitors.

Other targeted treatments, such as Janus kinase (JAK) inhibitors, may also be prescribed for ankylosing spondylitis. However, JAK inhibitors are targeted synthetic medicines rather than biologics, and their safety considerations are different.

What Are the Most Common Side Effects of Biologics?

Some side effects are temporary or manageable, while others can become bothersome enough to require treatment changes. The pattern depends on the specific medication, how it is given, and the person's medical circumstances.

Injection-site reactions

Many biologics are injected beneath the skin, commonly into the abdomen or thigh. Some people notice changes around the injection area afterward.

  • Redness or a change in skin color around the injection site
  • Itching or irritation
  • Local swelling or tenderness
  • Bruising
  • Pain or discomfort during or after injection

These reactions are often localized and may settle without additional treatment. However, increasing pain, warmth, spreading redness, or discharge should be assessed because these changes may indicate an infection rather than ordinary injection irritation.

Patients who inject their medication at home should follow the product instructions and the training provided by their healthcare team. Using the recommended injection sites and rotating between appropriate areas may help reduce local irritation.

Headaches and digestive discomfort

Headaches, nausea, and abdominal discomfort can occur with certain biologic medicines. For example, these effects are reported with adalimumab.

Some IL-17 inhibitors may cause diarrhea. A brief episode of digestive discomfort is not always a sign of a serious problem, but persistent diarrhea, unexplained weight loss, or significant abdominal pain deserves medical review.

Skin changes and rashes

Skin reactions may include itching or rashes. Although some are limited and manageable, a widespread rash, blistering, or a rash accompanied by swelling or breathing problems requires prompt assessment.

Biologic treatment can occasionally be associated with new inflammatory skin conditions. A dermatologist or rheumatologist may need to assess an unusual or persistent rash to determine whether the medicine could be contributing.

Upper respiratory infections

Colds and other respiratory infections are among the infections reported during biologic treatment. Symptoms may include a runny nose, sore throat, congestion, or cough.

These symptoms are common in everyday life, so their appearance does not necessarily mean that a biologic caused the infection. Nevertheless, infections during treatment deserve appropriate attention, particularly when symptoms persist or worsen.

Can Biologics Cause Serious Infections?

Serious infection is one of the most important potential risks of biologic therapy. Because these medicines affect immune responses, some infections may become more difficult for the body to control.

Infections that may be of concern include pneumonia, tuberculosis, serious bacterial infections, and certain fungal infections. The degree and type of risk differ between medications.

According to MedlinePlus information on adalimumab, this TNF inhibitor can increase the risk of serious infections and may cause inactive tuberculosis or hepatitis B infections to become active. Screening and treatment of certain infections may therefore be necessary before starting therapy.

Signs of infection that need attention

People receiving biologics should contact their healthcare team promptly when they develop symptoms that may suggest a significant infection. Examples include:

  • Fever, chills, or unexplained sweating
  • A cough that persists or becomes worse
  • Shortness of breath
  • Unusual weakness or marked tiredness
  • Pain or burning when urinating
  • Warm, painful, or increasingly swollen skin
  • Unexplained weight loss or night sweats
  • Persistent diarrhea or abdominal pain accompanied by other signs of illness

These symptoms can have several causes. A healthcare professional considers their timing, examination findings, medical history, and any necessary tests before deciding whether an infection or medication reaction is responsible.

Serious illness, such as severe breathlessness, confusion, or rapidly worsening symptoms, requires emergency medical care.

What Serious Side Effects Can TNF Inhibitors Cause?

TNF inhibitors have several important warnings beyond common injection reactions. These complications are not expected in most patients, but they matter when doctors assess whether a particular biologic is suitable.

Nerve-related problems

Rare neurological complications involving damage to the protective covering of nerves have been reported with TNF inhibitors. These are sometimes called demyelinating disorders.

Potential warning symptoms include new numbness, tingling, limb weakness, or changes in vision. Such symptoms should be evaluated promptly rather than assumed to be ordinary ankylosing spondylitis symptoms.

Heart failure concerns

Certain TNF inhibitors have been associated with new or worsening heart failure. This is particularly relevant for people with an existing history of heart disease.

New shortness of breath, swelling around the ankles or feet, or unexplained worsening fatigue should be discussed with a healthcare professional.

Blood problems and immune reactions

Rare blood-related problems have been reported with some TNF inhibitors. Possible warning signs include unusual bruising, unexplained bleeding, marked paleness, or persistent fever.

Some patients may also develop lupus-like reactions, which can involve a rash, joint symptoms, or other inflammatory findings. These reactions require medical assessment because their symptoms can overlap with other conditions.

Cancer-related warnings

Some TNF inhibitors carry warnings concerning lymphoma and other cancers, including certain skin cancers. Understanding the actual risk is complicated because inflammatory diseases and other treatments may also affect cancer risk.

A medication warning does not mean that cancer will develop. Doctors consider factors such as personal cancer history, age, other medicines, and the expected benefit of treatment when discussing these concerns.

The NHS patient information on adalimumab provides additional guidance about common side effects, infections, serious allergic reactions, and when medical advice is needed during treatment.

Can IL-17 Biologics Cause Gut Problems or Fungal Infections?

IL-17 inhibitors have some safety concerns that differ from those of TNF inhibitors. Two particularly relevant issues are inflammatory bowel disease and fungal infections.

Inflammatory bowel disease

Inflammatory bowel disease includes Crohn's disease and ulcerative colitis. These conditions cause ongoing inflammation in the digestive tract.

IL-17 inhibitors have been associated with new or worsening inflammatory bowel disease in some patients. This is important because people with ankylosing spondylitis may also have inflammatory bowel disease.

Symptoms that may warrant evaluation include persistent diarrhea, blood in the stool, abdominal pain, and unexplained weight loss.

Anyone with a history of Crohn's disease or ulcerative colitis should tell their rheumatologist before starting an IL-17 inhibitor. This history can influence which biologic is selected.

Candida and other infections

Candida is a type of fungus that can cause infections in areas such as the mouth or genital region. Fungal infections have been reported during treatment with IL-17 inhibitors.

Possible symptoms include white patches in the mouth, oral discomfort, or itching and irritation in affected areas. A clinician can determine whether antifungal treatment or a change in medication management is needed.

According to MedlinePlus information on secukinumab, this medicine may increase infection risk, and patients should discuss existing infections, tuberculosis exposure, inflammatory bowel disease, and vaccination needs with their healthcare team.

Which Biologic Side Effects Require Urgent Medical Care?

Some symptoms require faster attention than routine injection irritation or a mild headache.

Get emergency medical help for possible severe allergic reactions

Rarely, biologic medicines can trigger serious allergic reactions, including anaphylaxis.

  • Difficulty breathing or swallowing
  • Swelling of the tongue, throat, lips, or face
  • Sudden faintness or collapse
  • Rapidly developing hives accompanied by breathing or circulation problems

These symptoms require immediate emergency care. Do not take another dose of the suspected medicine while awaiting urgent medical assessment.

Contact your healthcare team promptly for other concerning symptoms

Persistent fever, a worsening cough, unusual bruising, a new neurological symptom, severe skin changes, or persistent bloody diarrhea should not be ignored.

Depending on the symptoms, the clinician may recommend an examination, laboratory tests, treatment for an infection, temporary interruption of the biologic, or additional investigation.

Who May Need Extra Safety Checks Before Starting a Biologic?

Doctors review medical history before prescribing biologics because some existing conditions can influence treatment safety.

Important factors to discuss include:

  • Previous tuberculosis or recent exposure: An inactive infection may need treatment before certain biologics are started.
  • Hepatitis B infection: Some biologics can increase the risk of viral reactivation.
  • Frequent or long-lasting infections: Recurrent infections may affect treatment decisions.
  • Heart failure: Certain TNF inhibitors may not be appropriate for some patients with heart failure.
  • Neurological disorders: A history of demyelinating disease may influence biologic selection.
  • Crohn's disease or ulcerative colitis: These conditions are particularly relevant when considering IL-17 inhibitors.
  • Previous cancer: The type of cancer, treatment history, and individual circumstances require careful discussion.
  • Other immune-suppressing medicines: Combining treatments can affect infection risk.

Pregnancy plans and breastfeeding should also be discussed before treatment. The available safety information differs between biologic medicines, so decisions should be individualized rather than assuming all biologics have identical risks.

What Tests and Monitoring Are Needed During Biologic Treatment?

Safety checks are an important part of biologic treatment for ankylosing spondylitis. Their purpose is to identify problems that may not be obvious from symptoms alone and to help the healthcare team decide whether treatment can continue safely.

Before starting treatment

A rheumatologist will generally review infection history, current medicines, previous medical conditions, and vaccination status.

Testing may include screening for tuberculosis and hepatitis B, along with blood tests selected according to the medication and individual medical history. Active infections may need treatment before a biologic is started.

During ongoing treatment

Follow-up appointments allow the clinician to assess both treatment effectiveness and possible adverse effects.

Monitoring may include checking for new infections, reviewing skin or digestive symptoms, assessing injection tolerance, and ordering blood tests when appropriate. The exact schedule depends on the biologic, other medicines, and the patient's health.

Patients should also tell their healthcare team about newly prescribed medicines, hospital admissions, or infections treated elsewhere. These details may affect the safety of the next biologic dose.

How Can You Reduce the Risk of Biologic Side Effects?

Not every side effect can be prevented. However, appropriate screening, correct medication use, and early communication with the healthcare team can improve treatment safety.

Review vaccinations before treatment

Vaccination status should be reviewed before starting a biologic. Some vaccines may be recommended before treatment begins, while live vaccines are generally avoided during treatment with certain biologics.

Patients should speak with their clinician before receiving vaccinations because the advice depends on the medicine and type of vaccine.

Use injections exactly as instructed

For biologics given at home, correct injection technique matters. Patients should receive training on preparing the medicine, selecting injection sites, and safely disposing of used needles.

Changing injection sites and avoiding damaged or irritated skin may reduce local discomfort. Storage instructions should also be followed carefully because biologic products can have specific temperature requirements.

Report infections early

Contacting the healthcare team when infection symptoms develop allows the clinician to assess whether treatment or dose scheduling should change.

Patients should not independently continue, skip, or restart doses during a significant illness without appropriate medical guidance. The decision depends on the infection and medication involved.

Keep track of new symptoms

A simple record of when symptoms began, how long they lasted, and whether they appeared after an injection can be useful during follow-up appointments.

For example, noting whether a rash repeatedly follows a dose or whether digestive symptoms persist between doses may help the clinician evaluate the pattern.

This information supports medical assessment but does not establish the cause of a symptom by itself.

Should You Stop a Biologic if You Develop Side Effects?

Not every side effect means the medicine must be stopped. The appropriate response depends on the type of reaction, its seriousness, and the benefit the medicine is providing.

A small injection-site reaction may be manageable without changing treatment. Persistent headaches, repeated infections, or troublesome digestive symptoms may require a closer review of the medication.

For a serious infection or significant allergic reaction, urgent assessment is necessary. The healthcare professional may advise withholding or discontinuing treatment while the problem is investigated or treated.

Stopping biologic treatment without a plan can allow ankylosing spondylitis symptoms to become active again. For this reason, routine treatment changes should be discussed with the prescribing rheumatologist.

Can You Switch to Another Biologic if Side Effects Continue?

Yes. Switching to another biologic may be an option when a medicine causes troublesome side effects or is not suitable because of another health condition.

Sometimes a different medicine within the same biologic group may be considered. In other situations, the rheumatologist may recommend treatment that targets a different inflammatory pathway.

For example, a history of inflammatory bowel disease can influence the choice between a TNF inhibitor and an IL-17 inhibitor. Other concerns, including heart failure, recurrent infections, and neurological conditions, may also affect the decision.

Switching treatment does not guarantee that all adverse effects will disappear. The risks and benefits of the replacement medication must also be reviewed.

Are Biologics Safe for Long-Term Use in Ankylosing Spondylitis?

Biologics can be used as long-term treatments for ankylosing spondylitis when they remain effective and appropriate for the patient. Long-term use requires ongoing review rather than assuming that safety checks are only needed at the beginning.

Many people benefit from sustained inflammation control. At the same time, infections and other possible complications remain relevant throughout treatment.

Doctors consider whether the biologic is improving pain, stiffness, physical function, and daily activities alongside any adverse effects or new medical conditions.

For some patients, continuing the same biologic is appropriate. For others, a treatment adjustment may offer a better balance between controlling ankylosing spondylitis and limiting medication-related problems.

The central goal is to maintain effective control of inflammation while recognizing side effects early and responding to them appropriately. Regular follow-up with a rheumatologist helps support that balance.

Frequently Asked Questions

Common questions about biologic medicine safety, side effects, and treatment decisions in ankylosing spondylitis.

Do all biologics for ankylosing spondylitis weaken the immune system?

Biologics used for ankylosing spondylitis change specific immune responses to reduce inflammation. This can increase susceptibility to certain infections, but the type and level of risk differ between medicines. They do not all affect the immune system in exactly the same way.

How long do side effects from biologic injections last?

Minor injection-site reactions may settle after a short period, while other side effects can persist or recur during treatment. There is no single duration that applies to every biologic or reaction. Symptoms that become worse, do not resolve, or interfere with daily life should be discussed with the prescribing healthcare team.

Can I take my biologic injection if I have a cold or fever?

Whether to proceed with a dose depends on the infection, symptoms, and prescribed biologic. A fever or suspected significant infection should be discussed promptly with the healthcare team before the next dose. The clinician may recommend delaying treatment until the illness has been assessed or resolved.

Can biologics for ankylosing spondylitis cause cancer?

Some biologics, particularly certain TNF inhibitors, have warnings about lymphoma and other cancers. The relationship between treatment and cancer risk is complex because underlying inflammatory diseases and other factors may contribute. The presence of a warning does not mean cancer will occur. Individual risk should be discussed with the treating rheumatologist.

Is it possible to change biologics because of side effects?

Yes. A rheumatologist may recommend another biologic if side effects are persistent, significant, or difficult to manage. The replacement depends on previous treatment response, other medical conditions, and the specific risks of each medicine. Patients should not change or stop prescribed biologics without medical guidance, except when emergency care is needed for a serious reaction.

Citations

  1. NHS – Ankylosing Spondylitis: Treatment
  2. Merck Manual Professional Edition – Ankylosing Spondylitis
  3. MedlinePlus – Adalimumab Injection: Drug Information
  4. NHS – Adalimumab: Uses and Side Effects
  5. MedlinePlus – Secukinumab Injection: Drug Information
Share this article